PEARL is currently undergoing essential maintenance and will be read only (no submissions or deposits). PEARL will be available again to deposit outputs early next week (week commencing 1st March 2021). For any queries contact email@example.com
Now showing items 1-1 of 1
Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification ...